Management of acute infectious diarrhea for children living in resource-limited settings

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 5, 2014, Pages 621-632

  O'Ryan G, Miguel ^a   Ashkenazi Hoffnung, Liat ^b,c   O'Ryan Soriano, Miguel A ^d   Ashkenazi, Shai ^b,c  

^a UNIVERSITY OF CHILE   (Chile)

^b Schneider Children Hospital   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d HOSPITAL ROBERTO DEL RÍO   (Chile)

Author keywords

acute diarrhea; Africa; antimicrobials; developing world; gastroenteritis; management; resource deprived; resource limited; treatment

Indexed keywords

AMPICILLIN; AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; DILOXANIDE FUROATE; DOXYCYCLINE; DRINKING WATER; METRONIDAZOLE; NALIDIXIC ACID; NEOMYCIN; NITAZOXANIDE; PAROMOMYCIN; PLACEBO; RIFAXIMIN; TINIDAZOLE; TRIMETHOPRIM; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE GASTROENTERITIS; AMEBIASIS; ANTIMICROBIAL THERAPY; BLOODY DIARRHEA; CAMPYLOBACTER; CAMPYLOBACTER ENTERITIS; CHILD; CHILD HEALTH CARE; CHILDHOOD MORTALITY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; DEVELOPING COUNTRY; DIARRHEA; DIARRHEAGENIC ESCHERICHIA COLI; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CHOICE; DRUG TOLERABILITY; ENTAMOEBA HISTOLYTICA; ENTEROTOXIGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GIARDIA; GIARDIASIS; HEALTH CARE ACCESS; HEALTH ECONOMICS; HIGH RISK POPULATION; HUMAN; INFECTIOUS DIARRHEA; INVASIVE DIARRHEA; LOWEST INCOME GROUP; MORBIDITY; OUTCOME ASSESSMENT; RECOMMENDED DRUG DOSE; RESOURCE LIMITED SETTING; REVIEW; ROTAVIRUS; SALMONELLA ENTERICA; SHIGELLA; SHIGELLOSIS; SINGLE DRUG DOSE; TREATMENT DURATION; VIBRIO CHOLERAE; WATER CONTAMINATION; WATERY DIARRHEA; ACUTE DISEASE; DISEASE MANAGEMENT; DYSENTERY, BACILLARY; ESCHERICHIA COLI INFECTIONS; FLUID THERAPY; HOSPITALIZATION; MICROBIOLOGY; PARASITOLOGY; POVERTY; PRESCHOOL CHILD; ROTAVIRUS INFECTIONS; VIROLOGY;

ACUTE DISEASE; ANTI-INFECTIVE AGENTS; CHILD, PRESCHOOL; CRYPTOSPORIDIOSIS; DEVELOPING COUNTRIES; DIARRHEA; DISEASE MANAGEMENT; DYSENTERY, BACILLARY; ESCHERICHIA COLI INFECTIONS; FLUID THERAPY; HOSPITALIZATION; HUMANS; POVERTY AREAS; ROTAVIRUS INFECTIONS;

EID: 84898951824     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.901168     Document Type: Review

References (75)

1. O'Ryan M, Lucero Y, O'Ryan-Soriano MA, Ashkenazi S. An update on management of severe acute infectious gastroenteritis in children. Expert Rev Anti Infect Ther 2010;8:671-2
2. World Health Organization. World Health Statistics 2012. WHO Press; Geneva, Switzerland: 2012
3. United Nations. The Millenium Development Goals Report 2013. New York, NY, USA: 2013
4. Gladstone BP, Ramani S, Mukhopadhya I, et al. Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med 2011;28:337-46
5. Ryan ET. The intestinal pathobiome: its reality and consequences among infants and young children in resource-limited settings. J Infect Dis 2013;208:1732-3
6. Mami T, Sobuz SU, Begum S, et al. Etiology of diarrhea in Bangladeshi infants in the first year of life using molecular methods. J Infect Dis 2013;208:1794-802
7. Boschi-Pinto C, Velebit L, Shibuya K. Estimating child mortality due to diarrhea in developing countries. Bull World Health Organ 2008;86:710-17
8. Walker CL, Aryee MJ, Boschi-Pinto C, Black RE. Estimating diarrhea mortality among young children in low and middle income countries. PLoS One 2012;7: e29151-63
9. Walker CL, Rudan I, Liu L, et al. Global estimate of childhood pneumonia and diarrhea. Lancet 2013;381:1405-16
10. Yongsi HB. Pathogenic microorganisms associated with childhood diarrhea in low-and-middle income countries: case study of Yaoundé - Cameroon. Int J Environ Res Public Health 2008;5:213-29
11. Opintan JA, Newman MJ, Ayeh-Kumi PF, et al. Pediatric diarrhea in southern Ghana: etiology and association with intestinal inflammation and malnutrition. Am J Trop Med Hyg 2010;83:936-43
12. Moyo SJ, Gro N, Matee MI, et al. Age specific aetiological agents of diarrhea in hospitalized children aged less than five years in Dar es Salaam, Tanzania. BMC Pediatr 2011;11:19
13. Randremanana R, Randrianirina F, Gousseff M, et al. Case-control study of the etiology of infant diarrheal disease in 14 districts in Madagascar. PLoS One 2012;7e44533-43
14. Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013;382:209-15
15. Muhsen K, Levine MM. A systematic review and meta-analysis of the association between Giardia lamblia and endemic pediatric diarrhea in developing countries. Clin Infect Dis. 2012;55(Suppl 4):S27, 1-93
16. Trehan I, Goldbach HS, LaGrone LN, et al. Antibiotics as part of the management of severe acute malnutrition. N Engl J Med 2013;365:425-35
17. Bachou H, Tylleskar T, Kaddu-Mulinwa DH, Tumwine JK. Bacteremia among severely malnourished children infected and uninfected with the human immunodeficiency virus-1 in Kampala, Uganda. BMC Infect Dis 2006;6: 160-4
18. Greenberg D, Marcu S, Melamed R, Lifshitz M. Shigella bacteremia: a retrospective study. Clin Pediatr 2003;42: 411-14
19. Ashkenazi S. Shigella infections in children: new insights. Semin Pediatr Infect Dis 2004;15:246-52
20. Guarino A, Albano F, Ashkenazi S, et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases: evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J Pediatr Gastroenterol Nutr 2008;46: S81-S184
21. Bennish ML, Khan WA, Begum M. Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteria type 1 infection in Bangladesh. Clin Infect Dis 2006;42:356-62
22. Christopher PR, David KV, John SM, Sankarapandian V. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev 2010(4):CD006784
23. Shiferaw B, Solghan S, Palmer A. Antimicrobial susceptibility patterns of Shigella isolates in Foodborne Diseases Active Surveillance Network sites, 2000-2010. Clin Infect Dis 2012; 54(Suppl 5):S548-63
24. Vrints M, Mairiaux E, Van Meervenne E. Surveillance of antibiotic susceptibility patterns among Shigella sonnei strains isolated in Belgium during 18-year period 1990 to 2007. J Clin Microbiol 2009;47: 1379-85
25. Reporter R, Pulido M, Bowen A, et al. Note from the field: outbreak of infections caused by Shigella sonnei with decreased susceptibility to azithromycin - Los Angeles, California, 2012. MMWR 2013;62:171-2
26. Boumghar-Bourtchai I, Mariani-Kurkdjian P, Bingen E. Macrolide-resistant Shigella sonnei. Emerg Infect Dis 2008;14:1297-9
27. Jue S, Hardee R, Overman M. Notes from the field: emergence of Shigella flexneri 2a resistant to ceftriaxone and ciprofloxacin - South Carolina, October 2010. MMWR 2010;59:1619-20
28. Basualdo W, Aerbo A. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr Infect Dis J 2003;22:374-7
29. Vinh H, Anh VT, Campbell JJ. A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children. PLoS Negl Trop Dis 2011;5e1264-7
30. Onwuezobe IA, Oshun PO, Odigwe CC. Antimicrobials for treating symptomatic non-typhoidal Salmonella infection. Cochrane Database Syst Rev 2012;11: CD001167
31. Shkalim V, Amir A, Samra Z, Amir Y. Characteristics of non-typhi Salmonella gastroenteritis associated with bacteremia in infants and young children. Infection 2012;40:285-9
32. Lee HY, Su LH, Tsai MH, et al. High rate of reduced susceptibility to ciprofloxacin and ceftriaxone among nontyphoid Salmonella clinical isolates in Asia. Antimicrob Agents Chemother 2009;53: 2696-9
33. Ternhag A, Asikainen T, Giesecke J. A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species. Clin Infect Dis 2007;44:696-700
34. Salazar-Lindo E, Bradley Sack R, Chea Woo E. Early treatment with erythromycin of Campylobacter jejuni-associated dysentery in children. J Pediatr 1986;109:355-3599
35. Vukelic D, Trkulja V, Salkovic-Petrisic M. Single oral dose of azithromycin versus 5 days of oral erythromycin or no antibiotics in treatment of Campylobacter enterocolitis in children: a prospective randomized assessor-blind study. J Pediatr Gastroenterol Nutr 2010;50:404-10
36. Hu Y, Ren J, Zhan M, et al. Efficacy of rifaximin in prevention of travelers' diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Travel Med 2012;19:352-6
37. Trehan I, Shulman RJ, Ou CN. A randomized, double-blind, placebo-controlled trial of rifaximin in the treatment of tropical enteropathy. Am J Gastroenterol 2009;104:2326-633
38. Wong CS, Mooney JC, Brandt Jr. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 2012;55:33-41
39. Geerdes-Fenge HE, Lobermann M, Nurnberg M, et al. Ciprofloxacin reduces the risk of hemolytic uremic syndrome in patients with Escherichia coli O104:H4- associated diarrhea. Infection 2013;41(3): 669-73
40. De la Cabada Bauche J, DuPont HL. New development in traveler's diarrhea. Gastroenterol Hepatol 2011;7:88-95
41. Kaushik JS, Gupta P, Faridi MM, Das S. Single dose azithromycin versus ciprofloxacin for cholera in children: a randomized controlled trial. Indian Pediatr 2010;47:309-15
42. Zaglool D, Khodari Y, Gazzaz Z, et al. Prevalence of intestinal parasites among patients of Al-Noor Specialist hospital, Makkah, Saudia Arabia. Oman Med J 2011;26:182-5
43. Kathure C, James D, Mulinge E, et al. Intestinal parasitic infections in children presenting with diarrhoea in outpatien and inpatien settings in an infromal settlement of Nairobi, Kenya. BMC Infect Dis 2013;13:243
44. Samie A, Guerrant RL, Barrett L, et al. Prevalence of intestinal parasitic and bacterial pathogens in diarrhoeal and non-diarroeal humans stoools from Vhembe district, South Africa. J Health Popul Nutr 2009;27:739-45
45. World Health Organization. WHO recommendations on the management of diarrhea and pneumonia in HIV-infected infants and children: integrated management of childhood illness (IMCI). ISBN 978 92 4 154808 3. World Health Organization; Geneva, Switzerland: 2010
46. Fox A. Saravolatz. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005;40:1173-80
47. Rossignol JF, Ayuob A, Ayers M. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebocontrolled study of nitazoxanide. J Infect Dis 2001;184:103-6
48. Amadi B, Mwiya M, Musuku J, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 2002;360:1375-80
49. Abubakar I, Aliyu SH, Arumugam C, et al. Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst Rev 2007;8:CD004932
50. Hewitt R, Yiannoutsos C, Higgs E, et al. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. Clin Infect Dis 2000;31:1084-92
51. Kadappu K, Nagaraja M, Rao P, et al. Azithromycin as treatment for cryptosporidiosis in human immunodeficiency virus disease. J Postgrad Med 2002;48:179-81
52. Uip D, Lima A, Amato V, et al. Roxithromycin treatment for diarrhea caused by Cryptosporidium spp. in patients AIDS. J Antimicrob Chemother 1998;41: 93-7
53. WHO/PAHO/UNESCO report: a consultation with experts on amoebiasis: mexico City, Mexico 28-29 January. Epidemiol Bull 1997;18:13-14
54. Blessmann J, Tannich E. Treatment of asymptomatic intestinal Entamoeba histolytica infection. N Engl J Med 2002;347:1384
55. Levecke B, Dreesen L, Barrionuevo-Samaniego M, et al. Molecular differentiation of Entamoeba spp. in a rural community of Loja province, South Ecuador. Trans R Soc Trop Med Hyg 2011;105:737-9
56. Leiva B, Lebbad M, Winiecka-Krusnell J, et al. Overdiagnosis of Entamoebahisto-lytica and Entamoeba dispar in Nicaragua. A microscopic, triage parasite panel and PCR study. Arch Med Res 2006;37:529-34
57. Ramos F, Mora'n P, Gonza'lez E, et al. High prevalence rate of Entamoeba histolytica asymptomatic infection in a rural Mexican community. Am J Trop Med Hyg 2005;73: 87-91
58. Shimokawa C, Kabir M, Taniuchi M, et al. Entamoeba moshkovskii is associated with diarrhea in infants and causes diarrhea and colitis in mice. J Infect Dis 2012;206(5): 744-51
59. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Giardia intestinalis and or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001;184(3): 381-4
60. Rossignol JF, Kabil SM, El Gohary Y, Younis AM. Nitazoxanide in the treatment of amoebiasis. Trans R Soc Trop Med Hyg 2007;101:1025-31
61. Haque R, Huston C, Hughes M, et al. Amebiasis. N Engl J Med 2003;348: 1565-73
62. Gonzales ML, Dans LF, Martinez EG. Antiamoebic drugs for treating amoebic colitis. Cochrane Database Syst Rev 2009;2: CD006085
63. Granados CE, Reveiz L, Uribe LG, et al. Drugs for treating giardiasis. Cochrane Database Syst Rev 2012;12:CD007787
64. Solaymani-Mohammadi S, Genkinger JM, Loffredo CA, Singer SM. A meta-analysis of the effectiveness of albendazole compared with metronidazole as treatments for infections with Giardia duodenalis. PLoS Negl Trop Dis 2010;11e682-91
65. American Academy of Pediatrics. Giardia intestinalis infections (Giardiasis). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, editors. Report of Committee on Infectious Diseases. 29th edition. American Academy of Pediatrics; Elk Grove Village, IL, USA: 2012. p. 333-5
66. Chandy E, McCarthy J. Evidence behind the WHO Guidelines: hospital care for children: what is the most appropriate treatment for giardiasis? J Trop Pediatr 2009;55:5-7
67. Ortiz JJ, Ayoub A, Gargala G, et al. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment Pharmacol Ther 2001;15:1409-15
68. Lalle M. Giardiasis in the post genomic era: treatment, drug resistance and novel therapeutic perspectives. Infect Disord Drug Targets 2010;10:283-94
69. World Health Organization. The Treatment of diarrhea: a manual for physicians and other senior health workers - 4th rev. ISBN 92 4 159318 0. World Health Organization; Geneva, Switzerland: 2005
70. Galvao T, Thees MF, Pontes RF, et al. Zinc supplementation for treating diarrhea in children: a systematic review and meta-analysis. Rev Panamer Salud Pu'blica 2013;33:370-7
71. Bhattacharya SK, Sur D, Ali M, et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2013;12:1050-6
72. Luquero FJ, Grout L, Ciglenecki I, et al. First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012. PLoS Negl Trop Dis 2013;10e2465-74
73. Barry EM, Pasetti MF, Sztein MB, et al. Progress and pitfalls in Shigella vaccine research. Nat Rev Gastroenterol Hepatol 2013;4:245-55
74. Holmgren J, Bourgeois L, Carlin N, et al. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant. Vaccine 2013;31:2457-64
75. Darsley MJ, Chakraborty S, DeNearing B, et al. The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease. Clin Vaccine Immunol 2012;12:1921-31